Equity in the Pandemic Treaty: Access and Benefit-Sharing as a Policy Device or a Rhetorical Device?

Hampton, Abbie-Rose; Eccleston-Turner, Mark; Rourke, Michelle; Switzer, Stephanie

doi:10.1017/jme.2023.59

Cited by 5 publications

(3 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Comments from sessions indicate that such concerns are increasingly being echoed by representatives of global north countries in the current Pandemic Agreement negotiations. Some critics have even argued that the proposals for PABS would block progress towards open science, in favour of a transactional approach 5 .…”

Section: Science-for-sciencementioning

confidence: 99%

Save lives in the next pandemic: ensure vaccine equity now

Carlson,

Becker,

Happi

et al. 2024

Nature

View full text Add to dashboard Cite

Section: Science-for-sciencementioning

confidence: 99%

Save lives in the next pandemic: ensure vaccine equity now

Carlson,

Becker,

Happi

et al. 2024

Nature

View full text Add to dashboard Cite

“…Notwithstanding the treaty's affirmation of the sovereign right of each Party to manage public health matters in line with its national legislation and policies [(10): Article 4.3], it delineates obligations and standards that may inadvertently impinge upon the autonomy of LDNs in shaping their health policies and priorities. For instance, while Article 10 mandates sharing biological materials, genetic data, and benefits arising from them (10), it lacks explicit safeguards to ensure that such sharing is predicated on the consent of LDNs and involves equitable benefit-sharing (48). Furthermore, the treaty, while specifying that the Governing Body shall consist of representatives from all Parties [(10): Article 20.1], subject to alternative arrangements in exceptional circumstances [(10): Article 20.3], does not detail the mechanisms of selecting these representatives nor guaranteeing that the unique challenges and contexts of LDNs are aptly reflected in governance processes.…”

Section: Challenges and Concerns For Ldns In The Pandemic Treatymentioning

confidence: 99%

Strategizing global health governance: unpacking opportunities and challenges for least developed nations within the WHO pandemic treaty framework

Jiang,

Kumah

2023

Front. Public Health

View full text Add to dashboard Cite

Exploring the intricacies of the proposed WHO pandemic treaty, this paper underscores its potential benefits and challenges for Least Developed Nations (LDNs) in the global health landscape. While the treaty could elevate LDNs’ access to vital resources, fortify health systems, and amplify their voice in global health governance, tangible challenges in safeguarding equitable access, protecting sovereignty, and ensuring compliance are illuminated. Concluding with targeted recommendations, the paper advocates for treaty revisions that assure resource access, safeguard LDNs’ autonomy, and foster capacity-building. In essence, the paper emphasizes the imperative of genuinely empowering LDNs, crafting a pandemic treaty that establishes a more equitable, resilient, and inclusive global health future.

show abstract

“…Current challenges of COVID-19 disease include limited access to vaccines and medications (5), reduced diagnostic testing to assess the true remaining impact of the disease (6), and increased susceptibility of vulnerable populations (i.e., increased age, comorbidities, and social deprivation) to severe disease (6,7). Numerous drugs have been shown to be safe and effective in treating patients with severe COVID-19 (i.e., corticosteroids, baricitinib, or IL-6 receptor blockers) (8), but few have been shown to prevent disease progression.…”

Section: Introductionmentioning

confidence: 99%

Regional moderate hyperthermia for mild-to-moderate COVID-19 (TherMoCoV study): a randomized controlled trial

Mancilla-Galindo,

Kammar-García,

Mendoza-Gertrudis

et al. 2023

Front. Med.

View full text Add to dashboard Cite

BackgroundTo prevent COVID-19 progression, low-cost alternatives that are available to all patients are needed. Diverse forms of thermotherapy have been proposed to prevent progression to severe/critical COVID-19.ObjectiveThe aim of this study is to evaluate the efficacy and safety of local thermotherapy to prevent disease progression in hospitalized adult patients with mild-to-moderate COVID-19.MethodsA multicenter, open-label, parallel-group, randomized, adaptive trial is used to evaluate the efficacy and safety of local thermotherapy to prevent disease progression in hospitalized adult patients with mild-to-moderate COVID-19. Eligible hospitalized adult patients with symptoms of COVID-19 with ≤5 days from symptom onset, meeting criteria for mild or moderate COVID-19, were randomly assigned to the intervention consisting of local thermotherapy via an electric heat pad in the thorax (target temperature range 39.5–42°C) continuously for 90 min, twice daily, for 5 days, or standard care. The main outcome was the proportion of patients who progressed to severe-to-critical COVID-19 or death. Patients were randomized in a 1:1 ratio through a centralized computer-generated sequence of minimization with a random component of 20%. Participants and medical staff were not blinded to the intervention.ResultsOne-hundred and five participants (thermotherapy n = 54, control n = 51) with a median age of 53 (IQR: 41–64) years were included for analysis after the early cessation of recruitment due to the closure of all temporal COVID-19 units (target sample size = 274). The primary outcome of disease progression occurred in 31.4% (16/51) of patients in the control group vs. 25.9% (14/54) of those receiving thermotherapy (risk difference = 5.5%; 95%CI: −11.8–22.7, p = 0.54). Thermotherapy was well tolerated with a median total duration of thermotherapy of 900 (IQR: 877.5–900) min. Seven (13.7%) patients in the control group and seven (12.9%) in the thermotherapy group had at least one AE (p = 0.9), none of which were causally attributed to the intervention. No statistically significant differences in serum cytokines (IL-1β, IL-6, IL-8, IL-10, IL-17, and IFN-γ) were observed between day 5 and baseline among groups.ConclusionLocal thermotherapy was safe and well-tolerated. A non-statistically significant lower proportion of patients who experienced disease progression was found in the thermotherapy group compared to standard care. Local thermotherapy could be further studied as a strategy to prevent disease progression in ambulatory settings.Clinical Trial registration: www.clinicaltrials.gov, identifier: NCT04363541.

show abstract

Equity in the Pandemic Treaty: Access and Benefit-Sharing as a Policy Device or a Rhetorical Device?

Cited by 5 publications

References 11 publications

Save lives in the next pandemic: ensure vaccine equity now

Save lives in the next pandemic: ensure vaccine equity now

Strategizing global health governance: unpacking opportunities and challenges for least developed nations within the WHO pandemic treaty framework

Regional moderate hyperthermia for mild-to-moderate COVID-19 (TherMoCoV study): a randomized controlled trial

Contact Info

Product

Resources

About